NDA approves Lenacapavir, a twice-yearly dose PrEP manufactured by Gilead
National Drug Authority has just approved Lenacapavir, a twice-yearly dose PrEP manufactured by Gilead, a USA based company. This is a game-changer for HIV prevention, especially for those at high risk. This is great step towards ending AIDS by 2030
